Evidence map›Paper›PMID 30555890›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2018

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume.

Emrah Düzel, David Berron, Hartmut Schütze, Arturo Cardenas-Blanco, Coraline Metzger, Matthew Betts, Gabriel Ziegler, Yi Chen, Laura Dobisch, Daniel Bittner and 30 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Reduced Repetition Suppression in Aging is Driven by Tau-Related Hyperactivity in Medial Temporal Lobe.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 12 institutions in 2 countries.

Emrah DüzelInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
David BerronInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Hartmut SchützeInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Arturo Cardenas-BlancoInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Coraline MetzgerInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Matthew BettsGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Gabriel ZieglerInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Yi ChenInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Laura DobischGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Daniel BittnerGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Wenzel GlanzGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Martin ReuterGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Annika SpottkeGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Janna RudolphGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Frederic BrosseronGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Daniel JanowitzInstitute for Stroke and Dementia Research, University Hospital, Munich, Germany.
Klaus FliessbachGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Michael HenekaGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Martina BuchmannGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Peter NestorGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Oliver PetersGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Dominik DiesingCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Berlin, Germany.
Siyao LiCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Berlin, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Eike Jakob SpruthDepartment of Psychiatry and Psychotherapy, Berlin, Germany.
Slawek AltensteinGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Alfredo RamirezDepartment of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Barbara KoflerDepartment of Neurodegeneration and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
Oliver SpeckDepartment of Biomagnetical Resonance, Magdeburg, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Ingo KilimannGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Martin DyrbaGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Jens WiltfangGerman Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
Claudia BartelsGerman Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
Steffen WolfsgruberGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Michael WagnerGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
German Center for Neurodegenerative Diseases · DEOtto-von-Guericke University Magdeburg · DEUniversity Hospital Bonn · DEUniversity Hospital Magdeburg · DEUniversity of Cologne · DEUniversity of Rostock · DECharité - Universitätsmedizin Berlin · DEFreie Universität Berlin · DEHertie Institute for Clinical Brain Research · DEMRB Research Center for Magnetic Resonance Bavaria · DEUniversity College London · GBUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe examined the association between cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, neural novelty responses, and brain volume in predementia old age.

methodsWe conducted a cross-sectional analysis of the observational, multicentric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study. Seventy-six participants completed task functional magnetic resonance imaging and provided CSF (40 cognitively unimpaired, 21 experiencing subjective cognitive decline, and 15 with mild cognitive impairment). We assessed the correlation between CSF biomarkers and whole-brain functional magnetic resonance imaging novelty responses to scene images.

resultsTotal tau levels were specifically and negatively associated with novelty responses in the right amygdala and right hippocampus. Mediation analyses showed no evidence that these associations were dependent on the volume of hippocampus/amygdala. No relationship was found between phosphorylated-tau or Aβ DISCUSSION: Our data show that CSF levels of total tau are associated with anatomically specific reductions in novelty processing, which cannot be fully explained by atrophy.

Indexed as

Alzheimer's disease (AD)Apolipoprotein E (APOE)Aβ42Cerebrospinal fluid (CSF)LongitudinalMagnetic resonance imaging (MRI)Mild cognitive impairment (MCI)Positron emission tomography (PET)Subjective cognitive decline (SCD)Tau

Identifiers

PMID30555890
PMCPMC6280588
OpenAlexW2898710646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.